Human onchocerciasis also known as river blindness is a debilitating disease with over 220 million people at risk worldwide. The epicentre of the disease is located in Africa [1]. The causative agent of human onchocerciasis is the filarial worm Onchocerca volvulus, which is transmitted by blackflies (genus Simulium), whose larvae develop in fast-running streams and rivers. In Africa, the main vectors which account for transmission of most cases of onchocerciasis belong to the Simulium damnosum complex of sibling species. These are known to disperse an average of 15 to 20km from their breeding site, hence the intensity of the disease is highest in villages 10km or less from a productive breeding site [2].
The burden of human onchocerciasis in Africa has necessitated the formation of large control programs to fight the disease. The Onchocerciasis Control Program (OCP) used large-scale aerial and ground insecticide application against the larval stages of the vectors to control the disease in West Africa. The OCP (1975–2002) successfully controlled onchocerciasis as a public health and socio-economic problem in most of its member countries [3]. The African Programme for Onchocerciasis Control (APOC) (1995–2015), using mainly mass community-directed treatment with ivermectin (CDTI) achieved more than control of onchocerciasis as a public health problem within its participating countries [4]. The initial objective of the APOC saw a paradigm shift from morbidity control to transmission elimination following proof of principle of transmission elimination with ivermectin in some foci in West Africa [5, 6]. The Expanded Special Project for the Elimination of Neglected Tropical Diseases in Africa (ESPEN), was set up in 2016 with responsibility against five preventive chemotherapy NTDs, including onchocerciasis. Amongst ESPEN responsibilities, are to scale up treatment, build health capacity of countries, improve the supply and effective use of the drugs and to increase resource mobilization to accelerate the control and transmission elimination of these diseases [7].
Many foci in former APOC countries have attained interruption/elimination of transmission (including foci in Ethiopia, Sudan, Uganda, Equatorial Guinea (Bioko Island) and Nigeria) using MDA alone or combined with vector control [8]. By 2021, about 2 million people formerly at risk of onchocerciasis in Latin America and Africa had become safe from such risk due to transmission interruption [1, 9]. This figure will likely increase as several countries have stopped MDA and are currently undertaking post-treatment surveillance (PTS) [9].
The 2021–2030 NTD roadmap targets transmission interruption of human onchocerciasis from 12 countries using ivermectin as the main treatment strategy [10]. Ivermectin drastically reduce skin microfilaridermia few days after administration, an effect which lasts for at least ten months, and also temporarily inhibits their release by gravid female worms for several months [11]. This leads to a reduction in intensity and prevalence of infection in the community thereby reducing the number of individuals who could infect the vector [12]. The goal is therefore to administer ivermectin for a period as long as the life span of the gravid female (15 to 17 years), preventing transmission until the natural death of the adult female worm occurs. Elimination of onchocerciasis using MDA requires sustained high annual MDA treatment coverage (> 80% of eligible population) for 15 to 20 years [13, 14]. The North region of Cameroon (precisely the Vina valley -Touboro health district) was one of the first areas in Africa where mass ivermectin distribution trials were carried out by 1987 [15, 16].
Savanna vectors play major role in onchocerciasis transmission in North region of Cameroon; where Simulium damnosum sensu stricto apparently serves as the major vector and S. sirbanum likely plays a secondary role [17]. A small number of larvae of forest vectors -S. squamosum cytotype A and S. mengense - periodically occur in the area [18, 19], possibly contributing to overall transmission. Vector breeding is seasonal in most of the region where the streams and rivers only flow during the rainy season, except for perennial rivers like the Benoue, Vina south and Mbere. Biting rates around the rivers and their tributaries are usually very high [20].
One major challenge with onchocerciasis in West and Central Africa is that the endemic foci are usually large and contiguous cutting across national and international boundaries [21, 22]. This poses a problem when independent projects or country programs on either side of such boundaries show heterogeneity in their progress towards transmission elimination. This is because an area or country can only be certified for transmission elimination when there is minimal risk of re-introduction of onchocerciasis [13]. With the vectors capable of travelling up to 20km, this makes cross-border transmission interruption amongst the main challenges of onchocerciasis elimination in Africa [23].
The North region of Cameroon is characterised by savanna bioecology and consequently the epidemiology of onchocerciasis is mostly manifested by ocular, rather than skin, complications [16]. The region is host to two major hyperendemic foci - Benue basin and Vina-Mbere/Touboro [24]. The Vina-Mbere/Touboro focus is a wide hyperendemic onchocerciasis cross-border focus continuous in Chad and Central African Republic, sustained by the Vina, Mbere and Lim (the three merge to form Logone Occidental) and Pende (called Logone Oriental in Chad) rivers in these countries [25]. Pre-control endemicity in the Vina-Mbere/Touboro focus were extremely high (CMFL of up to 303 mf/s – [26]) compared to levels in all other onchocerciasis endemic areas in the world, with some of such extremely high endemic (holoendemic) villages in Cameroon located close to the Chad border [4, 26].
Mass ivermectin distribution by health personel in the Cameroon side of the Vina-Mbere/Touboro focus began in 1987 [16], however, official records at the Touboro health district for mass drug administration (MDA) with ivermectin are available from 1993 [20]. Communities in the adjacent Rey Bouba and Tcholire health districts have had MDA since 1998. Historically, reported, as well as validated, annual treatment coverages in these districts have been very high, exceeding the 80% threshold required for elimination; validated treatment coverage from 2003 to 2009 ranged between 85.4–94.1% of eligible population [20]. Studies have shown that despite the several rounds, and high coverage, of ivermectin MDA in the Cameroon side of the border, active onchocerciasis transmission is still ongoing [20, 27], while (through MDA) border areas in Chad have either met the stop criteria or are close to doing so [4]. Given that annual MDA has been ongoing since the last evaluations in the area (2008–2010 – [20]), we sought to evaluate the current situation of onchocerciasis transmission in this cross-border area between Cameroon and Chad.